A Population-Based study to evaluate the severity of chronic obstructive pulmonary disease (COPD) in new users of aclidinium and other COPD medications in the United Kingdom (UK) and Denmark.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 31 May 2019

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Aclidinium bromide (Primary) ; Glycopyrrolate; Tiotropium bromide; Umeclidinium
Indications Chronic obstructive pulmonary disease
Focus Therapeutic Use

01 Jun 2019 Results evaluating the risk of death among users of aclidinium and other long-acting muscarinic antagonists published in the Respiratory Medicine
20 Sep 2017 New trial record
30 Aug 2017 Results presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com